Anti-CPT1A 抗体 [8F6AE9] (ab128568)
Key features and details
- Mouse monoclonal [8F6AE9] to CPT1A
- Suitable for: Flow Cyt, IHC-P, WB, ICC/IF, In-Cell ELISA
- Knockout validated
- Reacts with: Mouse, Rat, Human
- Isotype: IgG2b
Related conjugates and formulations
製品の概要
-
製品名
Anti-CPT1A antibody [8F6AE9]
CPT1A 一次抗体 製品一覧 -
製品の詳細
Mouse monoclonal [8F6AE9] to CPT1A -
由来種
Mouse -
アプリケーション
適用あり: Flow Cyt, IHC-P, WB, ICC/IF, In-Cell ELISAmore details -
種交差性
交差種: Mouse, Rat, Human -
免疫原
Recombinant fragment, corresponding to amino acids 489-773 of Human CPT1A.
-
ポジティブ・コントロール
- Partial Human Recombinant CPT1A protein; HepG2, H9C2, H4IIE Whole Cell Lysates; Rat heart mitochondrial, Human liver, Rat liver and Mouse liver homogenates; H9C2 cells; HeLa cells IHC-P: human normal kidney FFPE tissue sections
-
特記事項
This monoclonal antibody to CPT1A has been knockout validated in Western blot. The expected band for CPT1A was observed in wild type cells and the band was not seen in CPT1A knockout cells.
This antibody clone is manufactured by Abcam. If you require a custom buffer formulation or conjugation for your experiments, please contact orders@abcam.com.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
製品の特性
-
製品の状態
Liquid -
保存方法
Shipped at 4°C. Store at +4°C. Do Not Freeze. -
バッファー
pH: 7.4
Preservative: 0.02% Sodium azide
Constituent: HEPES buffered saline -
Concentration information loading...
-
精製度
Ammonium Sulphate Precipitation -
特記事項(精製)
Purity is near homogeneity as judged by SDS-PAGE. The antibody was produced in vitro using hybridomas grown in serum-free medium, and then concentrated by ammonium sulfate precipitation. -
ポリ/モノ
モノクローナル -
クローン名
8F6AE9 -
アイソタイプ
IgG2b -
軽鎖の種類
kappa -
研究分野
関連製品
-
Alternative Versions
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
-
Positive Controls
-
Related Products
アプリケーション
The Abpromise guarantee
Abpromise保証は、 次のテスト済みアプリケーションにおけるab128568の使用に適用されます
アプリケーションノートには、推奨の開始希釈率がありますが、適切な希釈率につきましてはご検討ください。
アプリケーション | Abreviews | 特記事項 |
---|---|---|
Flow Cyt |
Use at an assay dependent concentration.
|
|
IHC-P | (1) |
Use a concentration of 0.5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
|
WB | (3) |
Use a concentration of 1 µg/ml. Predicted molecular weight: 88 kDa.
|
ICC/IF | (1) |
Use a concentration of 0.5 - 5 µg/ml.
|
In-Cell ELISA |
Use a concentration of 0.1 - 1 µg/ml.
|
特記事項 |
---|
Flow Cyt
Use at an assay dependent concentration. |
IHC-P
Use a concentration of 0.5 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
WB
Use a concentration of 1 µg/ml. Predicted molecular weight: 88 kDa. |
ICC/IF
Use a concentration of 0.5 - 5 µg/ml. |
In-Cell ELISA
Use a concentration of 0.1 - 1 µg/ml. |
ターゲット情報
-
組織特異性
Strong expression in kidney and heart, and lower in liver and skeletal muscle. -
パスウェイ
Lipid metabolism; fatty acid beta-oxidation. -
関連疾患
Defects in CPT1A are the cause of carnitine palmitoyltransferase 1A deficiency (CPT1AD) [MIM:255120]; also known as CPT-I deficiency or CPT1A deficiency. CPT1AD is a rare autosomal recessive metabolic disorder of long-chain fatty acid oxidation characterized by severe episodes of hypoketotic hypoglycemia usually occurring after fasting or illness. Onset is in infancy or early childhood. -
配列類似性
Belongs to the carnitine/choline acetyltransferase family. -
細胞内局在
Mitochondrion outer membrane. - Information by UniProt
-
参照データベース
- Entrez Gene: 1374 Human
- Entrez Gene: 12894 Mouse
- Entrez Gene: 25757 Rat
- Omim: 600528 Human
- SwissProt: P50416 Human
- SwissProt: P97742 Mouse
- SwissProt: P32198 Rat
- Unigene: 503043 Human
see all -
別名
- Carnitine O palmitoyltransferase 1 liver isoform antibody
- Carnitine O palmitoyltransferase I antibody
- Carnitine O palmitoyltransferase I liver isoform antibody
see all
画像
-
Lane 1: Wild-type HAP1 cell lysate (20 µg)
Lane 2: CPT1A knockout HAP1 cell lysate (20 µg)
Lane 3: HeLa cell lysate (20 µg)
Lane 4: MCF-7 cell lysate (20 µg)Lanes 1 - 4: Merged signal (red and green). Green - ab128568 observed at 88 kDa. Red - loading control, ab181602, observed at 37 kDa.
ab128568 specifically detected the expected band for CPT1A in wild-type HAP1 cells. No band was observed in CPT1A knockout cells. Wild-type and CPT1A knockout samples were subjected to SDS-PAGE. ab128568 and ab181602 (loading control to GAPDH) were diluted at 1 μg/mL and 1/10000 respectively and incubated overnight at 4°C. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed (ab216772) and Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed (ab216777) secondary antibodies at 1/10000 dilution for 1 hour at room temperature before imaging. -
Immunofluorescent staining of CPT1A in H9C2 cells (rat) using ab128568.
Fixation: 4% paraformaldehyde PBS fixed for 20 minutes Permebilization: 0.1% Triton X-100 PBS for 30 minutes at room temperature while rocking
Blocking: 2x Sigma Block 0.1% Triton X-100 H2O for 2 hours at room temperature while rocking Primary antibodies: Anti-CPT1A antibody (ab128568) 0.5 ug/mL 1x Sigma Block with 0.1% Triton X-100 incubated overnight at 4 °C.
Washing: 3x 1% NGS 10 minutes/wash. Secondary antibodies: Alexa 488 GAM 1:1000 diluted in 1% NGS with 0.1% Triton X-100 PBS incubated for 2 hours at room temperature while rocking.
Washing: 3x 1% NGS 10 minutes/wash. DAPI: 20 ng/mL in 1% NGS, 0.1% Triton X-100 PBS.
Washing: 1x 1% NGS 10 minutes/wash. -
All lanes : Anti-CPT1A antibody [8F6AE9] (ab128568) at 1 µg/ml
Lane 1 : Marker
Lane 2 : Partial Human Recombinant CPT1A protein (ab128569) at 0.1 µg
Lane 3 : Full Length Human Recombinant OTC protein at 0.1 µg
Lane 4 : HepG2 (Human hepatocellular carcinoma cell line) Whole Cell Lysate at 20 µg
Lane 5 : H9C2 (Rat cardiomyoblast cell line) Whole Cell Lysate at 20 µg
Lane 6 : H4IIE ( Rat hepatoma cell line) Whole Cell Lysate at 20 µg
Lane 7 : RHM (Rat heart mitochondrial homogenate) at 20 µg
Lane 8 : HLH (Human liver homogenate) at 20 µg
Lane 9 : RLH (Rat liver homogenate) at 20 µg
Lane 10 : MLH (Mouse liver homogenate) at 20 µg
Secondary
All lanes : Goat polyclonal to Mouse IgG – H&L – Pre-Adsorbed (HRP) at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 88 kDa
Observed band size: 88 kDa
Exposure time: 1 minute
Predicted partial recombinant protein band size : 32 kDa Observed band size : 32 kDa -
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CPT1A antibody [8F6AE9] (ab128568)IHC image of CPT1A staining in human normal kidney formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab128568, 0.5µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.
For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times. -
Overlay histogram showing HeLa cells stained with ab128568 (red line) or no primary antibody (black line). The cells were fixed with 4% paraformaldehyde (15 min) and then permeabilized with 0.1% Triton X-100 in PBS, 3% BSA for 10 min. The cells were then incubated in 3% BSA in PBS for 10 minutes to block non-specific protein-protein interactions followed by the antibody (ab128568, 1µg/mL) for 60 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96871) at 1/1000 dilution for 30 min.
-
All lanes : Anti-CPT1A antibody [8F6AE9] (ab128568) at 1 µg/ml
Lane 1 : Marker
Lane 2 : HHH (Human heart homogenate) RIPA Extract Immunoprecipitated with no primary antibody
Lane 3 : HHH (Human heart homogenate) RIPA Extract Immunoprecipitated with Anti-CPT1A antibody 8F6AE9 (ab128568)
Lane 4 : HHH (Human heart homogenate) RIPA Extract 20 µg
Secondary
All lanes : Goat polyclonal to Mouse IgG – H&L – Pre-Adsorbed (HRP) at 1:10000
Developed using the ECL technique.
Performed under non-reducing conditions.
Predicted band size: 88 kDa
Exposure time: 1 minute -
In-Cell ELISA for Anti-CPT1A antibody (ab128568) stained HeLa cells (human)
Seeding: HeLa cells seeded in a 1:2 dilution series starting at 60,000 cells/well across Row A, 30,000 cells/well across Row B, etc. Row H contains no cells. Table: Example In-Cell ELISA Average Data from shown plate.
Fixation: 4% paraformaldehyde PBS fixed for 15 minutes Permeabilization: 0.3% Triton X-100 PBS for 30 minutes at room temperature while shaking
Blocking: 2x Sigma Block 0.3% Triton X-100 H2O for 2 hours at room temperature while shaking Primary antibodies: All primaries diluted in 1x Sigma Block with 0.3% Triton X-100 incubated overnight at 4 °C.
• Columns 1-3: Anti-CPT1A antibody (ab128568) 10 ug/mL • Columns 4-6: Anti-CPT1A antibody (ab128568) 1 ug/mL
• Columns 7-9: Anti-CPT1A antibody (ab128568) 0.1 ug/mL • Columns 10-12: No Primary
Washing: Briefly 4x with 0.3% TWEEN-20 PBS
データシートおよび資料
-
SDS download
-
Datasheet download
参考文献 (179)
ab128568 は 179 報の論文で使用されています。
- Rossi T et al. BETi enhance ATGL expression and its lipase activity to exert their antitumoral effects in triple-negative breast cancer (TNBC) cells. J Exp Clin Cancer Res 42:7 (2023). PubMed: 36604676
- Guo Z et al. Psoraleae Fructus Ethanol Extract Induced Hepatotoxicity via Impaired Lipid Metabolism Caused by Disruption of Fatty Acid β-Oxidation. Oxid Med Cell Longev 2023:4202861 (2023). PubMed: 36647431
- Hai Y et al. Icariin Alleviates Nonalcoholic Fatty Liver Disease in Polycystic Ovary Syndrome by Improving Liver Fatty Acid Oxidation and Inhibiting Lipid Accumulation. Molecules 28:N/A (2023). PubMed: 36677577
- Talari NK et al. Lipid-droplet associated mitochondria promote fatty-acid oxidation through a distinct bioenergetic pattern in male Wistar rats. Nat Commun 14:766 (2023). PubMed: 36765117
- Yau WW et al. Nicotinamide riboside rescues dysregulated glycolysis and fatty acid β-oxidation in a human hepatic cell model of citrin deficiency. Hum Mol Genet 32:1922-1931 (2023). PubMed: 36881658